HC Wainwright & Co. Reiterates Buy on Monte Rosa Therapeutics, Maintains $25 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor has reiterated a Buy rating on Monte Rosa Therapeutics (NASDAQ: GLUE) and maintained a price target of $25 for the stock.